Amphastar Pharmaceuticals Stock
Amphastar Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Yongfeng Zhang
- Employees
- 1,976
- Market cap
- $1.1 B
- IPO
- 25/06/2014
Amphastar Pharmaceuticals, Inc., established in 1996 and headquartered in Rancho Cucamonga, USA, is a biopharmaceutical enterprise listed on the NASDAQ. The company employs 1,976 employees and operates within the Healthcare sector as part of the Drug Manufacturers - Specialty & Generic industry. Amphastar's business…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
Amphastar Pharmaceuticals stock: price history
1D
-2.1%
1W
-2.8%
1M
+8.0%
6M
+13.1%
YTD
-3.4%
1Y
+11.4%
2Y
-49.1%
5Y
+35.4%
10Y
+43.7%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~112% stronger price swings than usual
Amphastar Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
1 more assignment (Enabler/Second row) Pro-only.
Amphastar Pharmaceuticals is a biopharmaceutical company engaged in the development, manufacturing, and distribution of generic and proprietary pharmaceuticals. Its portfolio encompasses various dosage forms including injections, inhalation products, and intranasal solutions for applications in emergency medicine and chronic disease treatment. In addition to finished pharmaceutical products, the company also operates as a manufacturer and distributor of active pharmaceutical ingredients (APIs). Business operations are primarily conducted in the U.S. market, with a customer base comprising a broad spectrum of healthcare providers including hospitals, clinics, and physician practices.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Low
Ask the agents about Amphastar Pharmaceuticals
Analyst assessment of Amphastar Pharmaceuticals
PRICE TARGET LOW
US$19.00
CONSENSUS
US$21.25
MEDIAN
US$21.50
PRICE TARGET HIGH
US$23.00
0
STRONG BUY
3
BUY
8
HOLD
1
SELL
0
STRONG SELL
12
TOTAL · Hold
As of: 18/08/2026
Amphastar Pharmaceuticals stock metrics
P/E
14.87
P/B
1.47
EV/EBITDA
8.19
RETURN ON EQUITY
4.0%
NET MARGIN
16.5%
DEBT/EQUITY
0.9
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
73.6%
FLOAT SHARES
31,293,039
AVG. DAILY VOLUME (30D)
511,193
Insider transactions (SEC)
PETERS WILLIAM J
Zhou Rong
Zhou Rong
Zhou Rong
PRINS RICHARD K
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Amphastar Pharmaceuticals stock
What does Amphastar Pharmaceuticals do?
Amphastar Pharmaceuticals, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Yongfeng Zhang, the company employs around 1,976 people.
The IPO was on 25/06/2014; the stock trades on NASDAQ under the ticker AMPH.
What do analysts say about Amphastar Pharmaceuticals stock?
12 analysts rate the stock, the consensus is Hold (as of 18/08/2026).
The average price target is US$21.25, ranging from US$19.00 to US$23.00, with a median of US$21.50.
This is an external assessment, not a statement by Market Jury.
When does Amphastar Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 112% stronger than usual.
Does Amphastar Pharmaceuticals pay a dividend?
Yes. The last dividend was US$0.30 per share, ex-date 11/06/2010, paid on 30/06/2010.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Amphastar Pharmaceuticals?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Aquestive Therapeutics.
How can I get Amphastar Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Amphastar Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.